Key Events This Week
21 Sep: Stock opens at Rs.100.80, down 0.64% amid broader Sensex gains
22 Sep: Mojo Grade upgraded to Hold as technicals and financials improve, stock rises 2.63% to Rs.103.45
23 Sep: Stock surges 6.77% to Rs.110.45 following rating upgrade and strong financial results
24 Sep: Valuation metrics improve, stock dips slightly by 0.41% to Rs.110.00 amid heavy volume
25 Sep: Golden Cross formation signals bullish breakout, stock closes at Rs.112.50, up 2.27%
21 September 2026: Week Opens with Slight Decline Amid Sensex Gains
The week began with Lactose (India) Ltd closing at Rs.100.80, down 0.64% from the previous Friday’s close of Rs.101.45. This decline came despite the Sensex gaining 0.46% to 35,787.64, reflecting some initial investor caution. The stock’s volume was relatively low at 4,556 shares, indicating subdued trading interest as the market awaited fresh catalysts.
22 September 2026: Mojo Grade Upgrade Spurs 2.63% Gain
On 22 September, the stock rebounded strongly, rising 2.63% to Rs.103.45 on increased volume of 11,337 shares. This move coincided with MarketsMOJO upgrading Lactose (India) Ltd’s investment rating from 'Sell' to 'Hold', citing improved technical indicators and robust financial performance. The upgrade was supported by a 37.7% growth in net sales to ₹92.74 crores over six months and a near doubling of profit after tax to ₹4.25 crores, signalling operational strength. The stock’s valuation was also deemed attractive, trading well below its 52-week high of Rs.136.45, with a PEG ratio of 0.2 highlighting undervaluation relative to earnings growth potential.
Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!
- - Clear entry/exit targets
- - Target price revealed
- - Detailed report available
23 September 2026: Strong Rally on Rating Upgrade and Financial Strength
The stock surged 6.77% to Rs.110.45 on heavy volume of 30,638 shares, marking the week’s highest close. This sharp gain followed the MarketsMOJO upgrade and was supported by the company’s highest quarterly PBDIT of ₹6.08 crores and a return on capital employed of 9.5%. The technical outlook improved from bearish to mildly bearish, signalling stabilisation in price momentum. Despite some mixed technical signals, the upgrade reflected growing confidence in the company’s earnings quality and valuation appeal relative to peers in the Pharmaceuticals & Biotechnology sector.
24 September 2026: Valuation Metrics Signal Renewed Price Attractiveness
On 24 September, the stock slipped marginally by 0.41% to Rs.110.00 on volume of 30,936 shares amid profit-taking. However, this dip belied a positive shift in valuation parameters. The P/E ratio improved to 20.07, significantly lower than many sector peers trading above 50, while the EV/EBITDA multiple stood at 10.35, indicating reasonable operational cash flow valuation. The PEG ratio of 0.26 further underscored undervaluation relative to earnings growth. These metrics prompted an upgrade in the valuation grade from very attractive to attractive, reinforcing the stock’s appeal within the micro-cap pharmaceutical segment.
Considering Lactose (India) Ltd? Wait! SwitchER has found potentially better options in and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - + beyond scope
- - Top-rated alternatives ready
25 September 2026: Golden Cross Formation Signals Potential Bullish Breakout
The week closed on a positive note with the stock rising 2.27% to Rs.112.50 on volume of 12,568 shares. This gain coincided with the formation of a Golden Cross, where the 50-day moving average crossed above the 200-day moving average, a classic bullish technical indicator suggesting a potential long-term trend reversal. Supporting indicators such as bullish daily moving averages and weekly MACD readings reinforced this positive momentum. Although some mixed signals persisted from weekly KST and Dow Theory assessments, the Golden Cross event marked a significant milestone, signalling growing investor confidence and a possible sustained uptrend.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-21 | Rs.100.80 | -0.64% | 35,787.64 | +0.46% |
| 2026-09-22 | Rs.103.45 | +2.63% | 35,672.04 | -0.32% |
| 2026-09-23 | Rs.110.45 | +6.77% | 35,870.78 | +0.56% |
| 2026-09-24 | Rs.110.00 | -0.41% | 35,291.38 | -1.62% |
| 2026-09-25 | Rs.112.50 | +2.27% | 35,353.29 | +0.18% |
Key Takeaways from the Week
Positive Signals: The upgrade to a Hold rating by MarketsMOJO on 22 September was a pivotal event, reflecting improved financial results with net sales growth of 37.7% and PAT nearly doubling. The stock’s valuation metrics improved markedly, with a P/E ratio of 20.07 and PEG ratio of 0.26, positioning it attractively against sector peers. The Golden Cross formation on 25 September further reinforced a potential bullish trend reversal, supported by bullish moving averages and MACD indicators.
Cautionary Notes: Despite the positive momentum, some technical indicators remain mixed, including bearish weekly KST and neutral Dow Theory signals, suggesting that confirmation of a sustained uptrend is still pending. The stock’s micro-cap status and pledged promoter shares (26.07%) introduce volatility and risk factors that investors should monitor. Additionally, the stock’s recent underperformance over the past year relative to the Sensex (-10.39% vs -8.95%) indicates that challenges remain in fully realising its growth potential.
Conclusion
Lactose (India) Ltd’s 10.89% weekly gain amid a declining Sensex highlights a notable shift in market sentiment driven by improved fundamentals, valuation, and technical outlook. The MarketsMOJO upgrade to Hold, combined with attractive valuation metrics and the formation of a Golden Cross, suggests that the stock may be entering a new phase of positive momentum. However, mixed technical signals and inherent micro-cap risks counsel a measured approach. Investors should continue to monitor quarterly financial results and technical confirmations to assess the sustainability of this rally within the Pharmaceuticals & Biotechnology sector.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
